Literature DB >> 14527676

Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation.

Elisabetta Aldieri1, Daniela Atragene, Loredana Bergandi, Chiara Riganti, Costanzo Costamagna, Amalia Bosia, Dario Ghigo.   

Abstract

Artemisinin is a natural product used as an alternative drug in the treatment of severe and multidrug-resistant malaria. In the present work we show that artemisinin shares with other sesquiterpene lactones the ability to inhibit the activation of the nuclear factor NF-kB: by this mechanism, artemisinin, as well as parthenolide, inhibits nitric oxide synthesis in cytokine-stimulated human astrocytoma T67 cells. These results suggest that artemisinin, in addition to its antiparasitic properties, could also exert a therapeutic effect on neurological complications of malaria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527676     DOI: 10.1016/s0014-5793(03)00905-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  40 in total

Review 1.  Effect of malaria components on blood mononuclear cells involved in immune response.

Authors:  Chuchard Punsawad
Journal:  Asian Pac J Trop Biomed       Date:  2013-09

2.  The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release.

Authors:  Jun Wang; Hong Zhou; Jiang Zheng; Juan Cheng; Wei Liu; Guofu Ding; Liangxi Wang; Ping Luo; Yongling Lu; Hongwei Cao; Shuangjiang Yu; Bin Li; Lezhi Zhang
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 3.  Spinal cord injury induced neuropathic pain: Molecular targets and therapeutic approaches.

Authors:  Dominic Schomberg; Gurwattan Miranpuri; Tyler Duellman; Andrew Crowell; Raghu Vemuganti; Daniel Resnick
Journal:  Metab Brain Dis       Date:  2015-01-15       Impact factor: 3.584

Review 4.  Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis.

Authors:  Manoj Kumar; Sunil Kumar Dhatwalia; D K Dhawan
Journal:  Tumour Biol       Date:  2016-09-10

Review 5.  Phytochemicals as potential IKK-β inhibitor for the treatment of cardiovascular diseases in plant preservation: terpenoids, alkaloids, and quinones.

Authors:  Fang Hua; Lingli Shi; Peng Zhou
Journal:  Inflammopharmacology       Date:  2019-09-05       Impact factor: 4.473

6.  Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation.

Authors:  Yanwei Wu; Shijun He; Bingxin Bai; Luyao Zhang; Lu Xue; Zemin Lin; Xiaoqian Yang; Fenghua Zhu; Peilan He; Wei Tang; Jianping Zuo
Journal:  Cell Mol Immunol       Date:  2015-03-16       Impact factor: 11.530

7.  Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.

Authors:  C Riganti; S Doublier; D Viarisio; E Miraglia; G Pescarmona; D Ghigo; A Bosia
Journal:  Br J Pharmacol       Date:  2009-03-09       Impact factor: 8.739

Review 8.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

9.  Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB.

Authors:  Hua Chen; Bei Sun; Shuangjia Wang; Shangha Pan; Yue Gao; Xuewei Bai; Dongbo Xue
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-26       Impact factor: 4.553

10.  Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza.

Authors:  Lisa M Alleva; Charles Cai; Ian A Clark
Journal:  Evid Based Complement Alternat Med       Date:  2009-09-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.